Cargando…

Lung ultrasound findings following COVID-19 hospitalization: A prospective longitudinal cohort study

BACKGROUND: Lung ultrasound (LUS) is a useful tool for diagnosis and monitoring in patients with active COVID-19-infection. However, less is known about the changes in LUS findings after a hospitalization for COVID-19. METHODS: In a prospective, longitudinal study in patients with COVID-19 enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Espersen, Caroline, Platz, Elke, Alhakak, Alia Saed, Sengeløv, Morten, Simonsen, Jakob Øystein, Johansen, Niklas Dyrby, Davidovski, Filip Søskov, Christensen, Jacob, Bundgaard, Henning, Hassager, Christian, Jabbari, Reza, Carlsen, Jørn, Kirk, Ole, Lindholm, Matias Greve, Kristiansen, Ole Peter, Nielsen, Olav Wendelboe, Jeschke, Klaus Nielsen, Ulrik, Charlotte Suppli, Sivapalan, Pradeesh, Iversen, Kasper, Stæhr Jensen, Jens Ulrik, Schou, Morten, Skaarup, Søren Helbo, Højbjerg Lassen, Mats Christian, Skaarup, Kristoffer Grundtvig, Biering-Sørensen, Tor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976570/
https://www.ncbi.nlm.nih.gov/pubmed/35453059
http://dx.doi.org/10.1016/j.rmed.2022.106826
Descripción
Sumario:BACKGROUND: Lung ultrasound (LUS) is a useful tool for diagnosis and monitoring in patients with active COVID-19-infection. However, less is known about the changes in LUS findings after a hospitalization for COVID-19. METHODS: In a prospective, longitudinal study in patients with COVID-19 enrolled from non-ICU hospital units, adult patients underwent 8-zone LUS and blood sampling both during the hospitalization and 2–3 months after discharge. LUS images were analyzed blinded to clinical variables and outcomes. RESULTS: A total of 71 patients with interpretable LUS at baseline and follow up (mean age 64 years, 61% male, 24% with acute respiratory distress syndrome (ARDS)) were included. The follow-up LUS was performed a median of 72 days after the initial LUS performed during hospitalization. At baseline, 87% had pathologic LUS findings in ≥1 zone (e.g. ≥3 B-lines, confluent B-lines or subpleural or lobar consolidation), whereas 30% had pathologic findings at follow-up (p < 0.001). The total number of B-lines and LUS score decreased significantly from hospitalization to follow-up (median 17 vs. 4, p < 0.001 and 4 vs. 0, p < 0.001, respectively). On the follow-up LUS, 28% of all patients had ≥3 B-lines in ≥1 zone, whereas in those with ARDS during the baseline hospitalization (n = 17), 47% had ≥3 B-lines in ≥1 zone. CONCLUSION: LUS findings improved significantly from hospitalization to follow-up 2–3 months after discharge in COVID-19 survivors. However, persistent B-lines were frequent at follow-up, especially among those who initially had ARDS. LUS seems to be a promising method to monitor COVID-19 lung changes over time. CLINICALTRIALS.GOV ID: NCT04377035.